Patient Experience
Patient Experience
Relationships with key stakeholders, including healthcare professionals, regulators, clinical groups, patients, and their communities deepen over time, adding significant value to the business and securing CSL’s license to operate. By working closely with patients, CSL can identify and pursue innovations that address unmet medical needs.
In recent years, the biopharmaceutical industry has acknowledged the central role of the patient, acknowledging that patients are the experts on the reality of living with their condition. CSL, which develops and manufactures medicines and vaccines, lists patient focus as its foremost value and, for several years, has actively supported outreach programs. One such initiative is the Center for Information and Study on Clinical Research Participation (CISCRP) which is focused on clinical trials and improving the patient experience. Additionally, CSL is a founding member of PALADIN (Patient Advocacy Leaders and Drug Development Industry Network), a new organisation dedicated to optimising collaboration between the industry and patient advocacy groups in researching new treatments, as well as engaging in the EUPATI (European Patient Academy on Therapeutic Innovation).
|
CSL’s Patient experience commitment CSL’s ambition is to elevate the Patient Experience in drug development by embedding patient insights and lived experience through patient-informed clinical development programs and formalising diversity plans to include representative populations. CSL’s Goals for 2030:
|
Diverse clinical trials
CSL understands the importance of diverse participation in clinical trials. Ideally, the mix of clinical trial participants would mirror the demographics of the population affected by the studied indication, yet minorities often remain underrepresented in clinical trials.
Participants in clinical trials help answer important questions about potential new treatments, paving the way for innovation that will benefit future patients. Participation may also offer patients the opportunity to be among the first to receive innovative treatments. Therefore, it is crucial that the composition of clinical trials reflects that of the general population.
For further details on CSL’s clinical trial practices please refer to: https://www.csl.com/research-and-development/clinical-studies/research-practices
Patient focus across the organisation
CSL continues to underscore its commitment to patient focus at both the global and local levels, identifying mutually beneficial ways to partner with patient stakeholders to address community needs and advance collective expertise across our therapeutic areas.
Recognising that health education and health equity are crucial elements of patient empowerment and pivotal components for successful collaboration with patients in the development of CSL therapies, CSL R&D partnered with Clinispan Health and local US Plasma centres to organise three community health summits. These summits, held in Raleigh, North Carolina, Philadelphia, Pennsylvania and Charlotte, North Carolina, featured keynote speakers and panel discussions including community-based healthcare leaders. The events aimed to educate minority and underserved populations about the importance of taking control of their health and the benefits of minority participation in clinical research. Combined, the summits attracted 250 in-person attendees and over 500 online viewers, with many expressing gratitude for the new insights gained and for CSL’s commitment to addressing healthcare disparities.